ProPath to Use CombiMatrix's Chromosomal Microarray Testing for Miscarriage Analysis | GenomeWeb

NEW YORK (GenomEWeb News) - CombiMatrix said today that it will provide chromosomal microarray analysis-based testing for miscarriage analysis for ProPath, a pathology services provider.

The agreement enables ProPath to add a new product to its suite of women's health diagnostics, one that "can play a significant role in a comprehensive miscarriage analysis," according to Kenneth Youens, ProPath's women's health director. He added that "the accuracy, clinical utility and quick turnaround times of CMA testing makes it a superior first tier testing option."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.